As of 2026-10-05, the Relative Valuation of Blueprint Medicines Corp (BPMC) is (62.49) USD. This relative valuation is based on P/E multiples. With the latest stock price at 129.46 USD, the upside of Blueprint Medicines Corp based on Relative Valuation is -148.3%.
The range of the Relative Valuation is (61.17) - (68.05) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.0x - 28.3x | 24.9x |
| Forward P/E multiples | 25.4x - 29.2x | 27.0x |
| Fair Price | (61.17) - (68.05) | (62.49) |
| Upside | -147.2% - -152.6% | -148.3% |
| Date | P/E |